Generic review appropriations
Executive Summary
The Senate Agriculture Appropriations bill reported by the full appropriations committee June 22 includes $10 mil. more for generic drug reviews than in the president's request. It exceeds the House version by $5 mil. The committee requests that FDA submit a report on any changes that have been made to the generic drug approval process. If the funding survives conference, it could end recently reignited debate over generic drug user fees (1"The Pink Sheet" Feb. 27, 2006, p. 8). The Senate bill fully funds the president's request for an additional $6 mil. for the Critical Path initiative and $4 mil. for drug safety activities (2"The Pink Sheet" Feb. 13, 2006, p. 9)...
You may also be interested in...
FDA To See Increased Funding, Oversight From Approps Committees In 2007
As the incoming chair of the House committee overseeing FDA's budget, Rep. Rosa DeLauro (D-Conn.) wants to increase agency funding - but not without the caveat of enhanced congressional oversight
FDA Faces Pricing Pressure As Generic Drug User Fee Debate Begins
Emerging discussions on the creation of a user fee program for generic drug review place FDA in the awkward position of potentially being seen as an arbiter of drug prices - at least indirectly
President’s Budget Paves The Critical Path With $6 Mil. Request
FDA requests $6 mil. and six FTEs for its Critical Path initiative in fiscal 2007, marking the first time funding has been proposed for the program